Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ABEO

Abeona Therapeutics Inc

May 15 • 04:00PM ET

4.71

Dollar change +0.51
Percentage change 12.14	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF ITOT IWC SURI DFAS IBRN AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.59	Insider Own	5.40%	Shs Outstand	39.64M	Perf Week	7.05%
Market Cap	186.70M	Forward P/E	-	EPS next Y	-1.56	Insider Trans	2.13%	Shs Float	37.50M	Perf Month	-39.30%
Income	-54.19M	PEG	-	EPS next Q	-0.45	Inst Own	48.58%	Short Float	8.92%	Perf Quarter	-23.41%
Sales	3.50M	P/S	53.34	EPS this Y	25.43%	Inst Trans	15.03%	Short Ratio	4.82	Perf Half Y	4.67%
Book/sh	-0.32	P/B	-	EPS next Y	17.14%	ROA	-119.62%	Short Interest	3.35M	Perf Year	52.92%
Cash/sh	1.58	P/C	2.98	EPS next 5Y	-	ROE	-1555.11%	52W Range	2.83 - 9.01	Perf YTD	-5.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	38.92%	ROI	-409.15%	52W High	-47.72%	Beta	1.51
Dividend TTM	-	Quick Ratio	4.15	Sales past 5Y	-15.07%	Gross Margin	8.63%	52W Low	66.43%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	5.61	EPS Y/Y TTM	8.58%	Oper. Margin	-1442.63%	RSI (14)	44.81	Volatility	10.51% 11.80%
Employees	84	Debt/Eq	-	Sales Y/Y TTM	227.72%	Profit Margin	-1548.23%	Recom	1.00	Target Price	19.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-114.59%	Payout	-	Rel Volume	1.59	Prev Close	4.20
Sales Surprise	0.00%	EPS Surprise	-125.99%	Sales Q/Q	-	Earnings	May 15 BMO	Avg Volume	693.93K	Price	4.71
SMA20	-0.29%	SMA50	-27.95%	SMA200	-7.16%	Trades		Volume	1,101,516	Change	12.14%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23
Jul-18-17	Reiterated	Maxim Group	Buy	$14 → $17
Jun-22-17	Resumed	Jefferies	Buy	$22
Jan-06-17	Initiated	Jefferies	Buy
Sep-29-16	Reiterated	Maxim Group	Buy	$8 → $14

Show Previous Ratings

Today 12:53PM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +12.14%
07:43AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress (GlobeNewswire)
May-07-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-03-24 11:19AM	Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise (MT Newswires) +13.02%
07:30AM	Loading…
07:30AM	Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Apr-23-24 02:04PM	Top Midday Decliners (MT Newswires) -53.67%
08:53AM	Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today? (InvestorPlace)
07:39AM	Top Premarket Decliners (MT Newswires)
07:09AM	FDA rejects Abeona cell therapy, asks for more manufacturing data (BioPharma Dive)
Apr-22-24 05:58PM	Abeona Therapeutics Shares Slump After Plans to Reapply for Pz-cel Drug Approval (MT Newswires)
04:27PM	UPDATE 1-US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:14PM	US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:05PM	Abeona Therapeutics Provides Regulatory Update on Pz-cel (GlobeNewswire)
Apr-01-24 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.48%
06:53AM	Loading…
Mar-19-24 06:53AM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +8.30%
05:31AM	Abeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial Results (GuruFocus.com)
Mar-18-24 07:30AM	Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections (GlobeNewswire) -19.00%
Mar-05-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.32%
Feb-15-24 05:52AM	Steven Cohen's Firm Increases Stake in Abeona Therapeutics Inc (GuruFocus.com) +5.53%
Feb-01-24 04:05PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65%
07:30AM	Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA) (GlobeNewswire)
Jan-08-24 07:30AM	Abeona Therapeutics Announces $50 Million Credit Facility (GlobeNewswire)
Dec-15-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-23 07:30AM	Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) (GlobeNewswire) +11.60%
Nov-17-23 10:09AM	Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:29AM	Q3 2023 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.56%
Nov-13-23 12:23PM	Abeona Therapeutics Inc (ABEO) Reports Q3 2023 Financial Results and Advances in Commercial ... (GuruFocus.com) +10.02%
07:41AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments (GlobeNewswire)
07:30AM	Loading…
Nov-01-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-23 07:30AM	Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) +9.84%
Sep-12-23 12:48PM	3 Biotech Blockbusters to Turn $5,000 Into $50,000 (InvestorPlace)
07:30AM	Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer (GlobeNewswire)
Sep-07-23 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-23 07:30AM	Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission (GlobeNewswire) +5.60%
Aug-11-23 07:41AM	ABEO: On Track to File BLA in 3Q23... (Zacks)
Aug-08-23 08:27AM	Abeona Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:30AM	Abeona Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 07:30AM	Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023 (GlobeNewswire) +5.37%
Jul-19-23 08:30AM	Abeona Therapeutics Joins Rare Disease Company Coalition (GlobeNewswire)
Jul-07-23 08:30AM	Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-03-23 08:45AM	Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +6.95%
Jun-09-23 07:30AM	Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101 (GlobeNewswire)
Jun-01-23 07:30AM	Abeona Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 08:00AM	ABEO: Additional Phase 3 VIITAL Data Presented at ISID Meeting (Zacks Small Cap Research)
May-25-23 12:27AM	Q1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference Call (Thomson Reuters StreetEvents)
May-22-23 07:30AM	Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023 (GlobeNewswire)
May-16-23 09:00AM	Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
May-13-23 08:15AM	Abeona Therapeutics First Quarter 2023 Earnings: US$0.54 loss per share (vs US$3.59 loss in 1Q 2022) (Simply Wall St.)
May-11-23 07:54AM	Abeona Therapeutics: Q1 Earnings Snapshot (AP Finance) -7.19%
07:30AM	Abeona Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
07:00AM	Abeona Therapeutics Announces Additional Phase 3 VIITAL Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting (GlobeNewswire)
Apr-18-23 07:15AM	ABEO: Initiating Coverage of Abeona Therapeutics Inc.; Using Gene Therapy to Treat Orphan Diseases (Zacks Small Cap Research)
Apr-10-23 07:30AM	Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
Mar-31-23 06:22AM	Companies Like Abeona Therapeutics (NASDAQ:ABEO) Could Be Quite Risky (Simply Wall St.)
Mar-29-23 07:30AM	Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants (GlobeNewswire) +11.52%
Mar-16-23 07:30AM	Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting (GlobeNewswire)
Mar-14-23 07:30AM	Abeona Therapeutics Announces Update on AAV Ophthalmology Program (GlobeNewswire)
Nov-14-22 07:30AM	Abeona Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -5.47%
Nov-08-22 02:28PM	Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario' (Benzinga)
Nov-03-22 12:44PM	Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder (Benzinga) -13.23%
07:31AM	Abeona Therapeutics Announces $35 Million Private Placement Financing (GlobeNewswire)
07:30AM	Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL Study of EB-101 (GlobeNewswire)
Oct-19-22 07:30AM	Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire) -8.09%
Oct-04-22 07:30AM	Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Sep-22-22 07:30AM	Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire) -9.22%
Sep-13-22 07:30AM	Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire)
Sep-08-22 08:48AM	10 Best Penny Stocks to Buy in September (Insider Monkey)
Aug-11-22 07:30AM	Abeona Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +12.02%
Jul-20-22 07:30AM	Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Jun-24-22 10:08AM	F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm (Zacks) -8.94%
Jun-13-22 01:27PM	FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy (Zacks) -6.18%
Jun-10-22 03:30PM	FDA Committee Recommends bluebird's (BLUE) CALD Therapy (Zacks)
Jun-08-22 01:21PM	bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy (Zacks) +8.49%
Jun-06-22 02:04PM	AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half (Zacks)
07:30AM	Abeona Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-22 02:25PM	BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug (Zacks) -7.84%
May-31-22 02:27PM	Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe (Zacks)
May-25-22 02:29PM	Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease (Zacks)
May-23-22 03:32PM	Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal (Zacks)
May-19-22 03:02PM	Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops (Zacks)
07:30AM	Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire)
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -7.03%
11:47AM	Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate (Zacks)
May-17-22 09:27AM	AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug (Zacks)
08:00AM	Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics (GlobeNewswire)
May-13-22 07:30AM	Abeona Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-12-22 02:47PM	AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals (Zacks) +15.09%
May-11-22 02:28PM	Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates (Zacks) -14.69%
May-10-22 02:36PM	Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates (Zacks)
11:37AM	Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down (Zacks)
May-06-22 03:48PM	Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -9.37%
03:38PM	ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates (Zacks)
May-04-22 07:30AM	Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates (GlobeNewswire)
May-03-22 07:00AM	Dianthus, a new $100M startup, aims to make autoimmune treatments easier (American City Business Journals)
Apr-29-22 09:00AM	Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire) -7.07%
07:30AM	Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock (GlobeNewswire)
Apr-19-22 10:51AM	Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth? (Simply Wall St.)

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Charles Faith L.	Director	Apr 26 '24	Buy	3.28	7,550	24,764	78,323	Apr 29 08:30 AM
Seshadri Vishwas	Chief Executive Officer	Apr 25 '24	Buy	3.20	10,000	32,000	538,260	Apr 29 08:30 AM
O'Malley Brendan M.	SVP, General Counsel	Apr 25 '24	Buy	3.24	8,600	27,864	188,718	Apr 26 08:30 AM
Vazzano Joseph Walter	Chief Financial Officer	Apr 25 '24	Buy	3.14	5,608	17,609	233,868	Apr 26 08:30 AM
Seshadri Vishwas	Chief Executive Officer	Feb 06 '24	Buy	4.39	20,000	87,800	528,260	Feb 07 08:30 AM
Alvino Mark	Director	Jan 17 '24	Sale	5.11	7,084	36,199	62,816	Jan 22 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 27 '23	Buy	4.07	20,000	81,400	521,731	Sep 29 07:30 AM
Charles Faith L.	Director	Sep 27 '23	Sale	4.91	8,330	40,924	70,773	Sep 29 04:30 PM
Alland Leila	Director	Sep 27 '23	Sale	3.90	7,246	28,270	71,857	Sep 29 04:30 PM
Alvino Mark	Director	Sep 27 '23	Sale	3.91	6,316	24,724	69,900	Sep 29 04:30 PM
Silverstein Christine Berni	Director	Sep 27 '23	Sale	3.91	6,330	24,721	87,884	Sep 29 04:30 PM
Amoroso Michael	Director	Sep 27 '23	Sale	3.91	5,508	21,542	108,957	Sep 29 04:30 PM
Amoroso Michael	Director	Sep 20 '23	Sale	3.90	327	1,275	114,465	Sep 22 04:05 PM
Vazzano Joseph Walter	Chief Financial Officer	Sep 19 '23	Buy	3.82	3,000	11,458	238,179	Sep 20 09:00 AM
O'Malley Brendan M.	SVP, General Counsel	Sep 18 '23	Buy	3.80	3,000	11,400	187,421	Sep 19 09:00 AM
Amoroso Michael	Director	Jun 20 '23	Sale	4.45	338	1,504	114,792	Jun 21 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABEO

Abeona Therapeutics Inc

Upgrade your FINVIZ experience